Treatment of COVID-19 with fluvoxamine reduces risk of prolonged hospitalisation, finds largest trial to date
The fluvoxamine arm of the TOGETHER trial, a randomised adaptive platform trial investigating the efficacy of repurposed treatments for COVID-19 among high-risk Brazilian adult outpatients, is the largest trial of the SSRI fluvoxamine as a COVID-19 treatment to date. Of the 741 participants who were treated in an emergency setting for COVID-19 after receiving fluvoxamine,…